Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

ClinicalTrials.gov ID: NCT04171141

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04171141. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors

Study identification

NCT ID: NCT04171141
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 79 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2019 (Actual)
Primary completion: Nov 28, 2023 (Actual)
Completion: Nov 28, 2023 (Actual)
Last update posted: Jan 16, 2025

2019 – 2023

United States locations

U.S. sites: 15
U.S. states: 6
U.S. cities: 9

Facility	City	State	ZIP	Site status
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte	California	91010	—
City of Hope IDS Pharmacy	Duarte	California	91010	—
UCLA Department of Medicine: Hematology-Oncology	Los Angeles	California	90055	—
UCLA Hematology Oncology - Santa Monica	Santa Monica	California	90404	—
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)	Aurora	Colorado	80045	—
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)	Aurora	Colorado	80045	—
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)	Aurora	Colorado	80045	—
START Midwest	Grand Rapids	Michigan	49546	—
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion	New York	New York	10022	—
Evelyn H. Lauder Breast and Imaging Center	New York	New York	10065	—
Memorial Sloan Kettering Cancer Center - Main Campus	New York	New York	10065	—
University Hospitals Cleveland Medical Center	Cleveland	Ohio	44106	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
Christus Santa Rosa Hospital	San Antonio	Texas	78229	—
NEXT Oncology	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04171141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 16, 2025 · Synced Nov 15, 2026